1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,206 | 0,258 | 23.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HVIVO Aktie jetzt für 0€ handeln | |||||
| Di | hVIVO secures largest standalone lab contract to date | 4 | Sharecast | ||
| Di | hVIVO subsidiary hLAB wins largest contract to date with US client | 2 | Alliance News | ||
| Di | hVIVO PLC - £3.2m hLAB project | 1 | RNS | ||
| 13.01. | hVIVO completes pilot study for hMPV challenge model | 2 | Sharecast | ||
| 13.01. | hVIVO PLC - hMPV challenge model update | 1 | RNS | ||
| 02.01. | hVIVO (LON:HVO) Stock Price Down 6.8% - Here's What Happened | 1 | MarketBeat | ||
| 24.12.24 | hVIVO (LON:HVO) Shares Cross Below 50 Day Moving Average - Here's What Happened | 1 | MarketBeat | ||
| 12.12.24 | hVIVO reports breakthrough in COVID-19 biomarker study | 2 | Investing.com | ||
| 12.12.24 | hVIVO PLC - COVID-19 study published in Nature Communications | - | RNS | ||
| 10.12.24 | Hvivo strikes £11.5m RSV contract with existing client | 2 | Sharecast | ||
| 10.12.24 | hVIVO PLC - £11.5m RSV contract and notice of trading update | - | RNS | ||
| 05.11.24 | hVIVO PLC - Presentation at Jefferies London Healthcare Conf | 1 | RNS | ||
| 11.10.24 | hVIVO PLC - Long Term Incentive Plan/ PDMR Notification | - | RNS | ||
| 07.10.24 | hVIVO upbeat on positive human challenge trial results with client | 1 | Sharecast | ||
| 07.10.24 | hVIVO PLC - Positive results from RSV human challenge trial | 1 | RNS | ||
| 30.09.24 | hVIVO gets HSE clearance, launches new lab services | 2 | Sharecast | ||
| 30.09.24 | hVIVO PLC - Launch of full suite of hLAB standalone services | - | RNS | ||
| 10.09.24 | hVIVO hails "record" half-year revenue, as profit soars 70% higher | 2 | Alliance News | ||
| 10.09.24 | Clinical trial specialist hVivo's H1 revenues jump by 30% | 1 | RTE.ie | ||
| 10.09.24 | hVIVO PLC - Interim results | 1 | RNS |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 1,170 | +1,56 % | Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix | CANBERA (dpa-AFX) - Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope... ► Artikel lesen | |
| SPINEWAY | 0,101 | -24,91 % | Spineway: 2024 revenue of €12 million - 14% growth compared with 2023 | Press release Ecully, January 22, 2025 - 6.30 p.m. SPINEWAY 2024 revenue of €12 million 14% growth compared with 2023 In thousands of euros20242023Change as a %H1 revenue6,5355,431+20%H2... ► Artikel lesen | |
| ASENSUS SURGICAL | 0,305 | 0,00 % | KARL STORZ akquiriert den US-amerikanischen Robotik-Spezialisten Asensus Surgical | Tuttlingen / Research Triangle Park, USA (ots) - Das familiengeführte und international agierende Medizintechnikunternehmen KARL STORZ gibt die Akquisition des innovativen Robotik-Spezialisten Asensus... ► Artikel lesen | |
| MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve president, CEO Preiner resigns | ||
| LIFEWARD | 1,530 | -0,65 % | Lifeward Ltd.: Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities | MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), today issued an open letter from Larry Jasinski, Chief Executive... ► Artikel lesen | |
| JD HEALTH | 3,640 | -1,62 % | JD Health-Aktie mit Kursgewinnen (3,70 €) | Im Plus liegt gegenwärtig die Aktie von JD Health . Zuletzt zahlten Investoren für das Papier 3,70 Euro. Für die Aktie von JD Health steht gegenwärtig ein Kursplus 4,23 Prozent zu Buche. Das Wertpapier... ► Artikel lesen | |
| EKSO BIONICS | 0,630 | +1,29 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Announces Third Quarter 2024 Financial Results | SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today... ► Artikel lesen | |
| IMUNON | 0,910 | -1,09 % | Imunon, Inc.: IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer | Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future... ► Artikel lesen | |
| ROCKWELL MEDICAL | 2,060 | -1,25 % | ROUNDUP/Aktien New York: Erneute Dow-Verluste - Nasdaq-Rally pausiert | NEW YORK (dpa-AFX) - An den US-Börsen bahnt sich am Dienstag für den Dow Jones Industrial der neunte Schwächetag in Folge an. Anders als zuletzt wird der US-Leitindex dabei aber von den anderen US-Indizes... ► Artikel lesen | |
| AVINGER | 0,556 | 0,00 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| VIRIDIAN THERAPEUTICS | 17,900 | 0,00 % | Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data | WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 3,180 | -0,62 % | SINTX Technologies, Inc.: SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 | Salt Lake City, UT, Nov. 14, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components... ► Artikel lesen | |
| AETHLON MEDICAL | 0,610 | -3,17 % | Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update | Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid... ► Artikel lesen | |
| STAGEZERO LIFE SCIENCES | 0,028 | 0,00 % | Stagezero Life Sciences Ltd (2): Stagezero loses $1.43-million (U.S.) in nine months | ||
| ARCH THERAPEUTICS | - | - | Arch Therapeutics, Inc. - 8-K, Current Report |
HVIVO PLC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,97 % bei einem Aktienkurs von 0,204 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.
